JP6723217B2 - Ｐｄｅ４阻害剤としての新規２，５−置換ピリミジン - Google Patents

Info

Publication number

JP6723217B2

JP6723217B2 JP2017502119A JP2017502119A JP6723217B2 JP 6723217 B2 JP6723217 B2 JP 6723217B2 JP 2017502119 A JP2017502119 A JP 2017502119A JP 2017502119 A JP2017502119 A JP 2017502119A JP 6723217 B2 JP6723217 B2 JP 6723217B2

Authority

JP

Japan

Prior art keywords

alkyl

alkylene

mmol

compound

substituted

Prior art date

2014-07-16

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Expired - Fee Related

Links

• Espacenet
• Global Dossier
• Discuss

• 150000003230 pyrimidines Chemical class 0.000 title claims description 28
• 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 title description 8
• 239000002587 phosphodiesterase IV inhibitor Substances 0.000 title description 8
• 150000001875 compounds Chemical class 0.000 claims description 240
• -1 N-pyrrolidinyl Chemical group 0.000 claims description 115
• 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 95
• 239000000203 mixture Substances 0.000 claims description 55
• 125000001424 substituent group Chemical group 0.000 claims description 53
• 229910052739 hydrogen Inorganic materials 0.000 claims description 51
• 229910052757 nitrogen Chemical group 0.000 claims description 35
• 125000004433 nitrogen atom Chemical group N* 0.000 claims description 32
• 229910002091 carbon monoxide Inorganic materials 0.000 claims description 27
• 239000001257 hydrogen Substances 0.000 claims description 27
• 125000000217 alkyl group Chemical group 0.000 claims description 25
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 25
• 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims description 24
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 23
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 20
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 19
• 201000010099 disease Diseases 0.000 claims description 18
• 239000003814 drug Substances 0.000 claims description 18
• 229910052736 halogen Inorganic materials 0.000 claims description 18
• 150000002367 halogens Chemical class 0.000 claims description 18
• 208000027866 inflammatory disease Diseases 0.000 claims description 17
• 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 15
• 102000004190 Enzymes Human genes 0.000 claims description 15
• 108090000790 Enzymes Proteins 0.000 claims description 15
• 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 15
• 125000002950 monocyclic group Chemical group 0.000 claims description 15
• 229910052717 sulfur Inorganic materials 0.000 claims description 15
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 14
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 14
• 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 11
• 125000002619 bicyclic group Chemical group 0.000 claims description 11
• 229910052760 oxygen Inorganic materials 0.000 claims description 11
• 125000000714 pyrimidinyl group Chemical group 0.000 claims description 11
• 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 10
• NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 10
• 239000001301 oxygen Substances 0.000 claims description 10
• 239000011593 sulfur Chemical group 0.000 claims description 10
• 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims description 9
• 206010028980 Neoplasm Diseases 0.000 claims description 9
• 150000001408 amides Chemical class 0.000 claims description 9
• 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 9
• 125000002541 furyl group Chemical group 0.000 claims description 9
• 125000001072 heteroaryl group Chemical group 0.000 claims description 9
• 230000005764 inhibitory process Effects 0.000 claims description 9
• 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims description 8
• 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 8
• 208000020925 Bipolar disease Diseases 0.000 claims description 8
• 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 claims description 8
• 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims description 8
• 201000000028 adult respiratory distress syndrome Diseases 0.000 claims description 8
• 230000000172 allergic effect Effects 0.000 claims description 8
• 208000028683 bipolar I disease Diseases 0.000 claims description 8
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 8
• 150000003839 salts Chemical class 0.000 claims description 8
• 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 7
• 239000002253 acid Substances 0.000 claims description 7
• 125000004076 pyridyl group Chemical group 0.000 claims description 7
• 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 6
• 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 6
• 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 6
• GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 claims description 6
• 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 6
• 208000011688 Generalised anxiety disease Diseases 0.000 claims description 6
• 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 6
• 201000011510 cancer Diseases 0.000 claims description 6
• 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims description 6
• 208000035475 disorder Diseases 0.000 claims description 6
• 208000029364 generalized anxiety disease Diseases 0.000 claims description 6
• 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 6
• 125000004430 oxygen atom Chemical group O* 0.000 claims description 6
• 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 6
• 125000001544 thienyl group Chemical group 0.000 claims description 6
• 206010001889 Alveolitis Diseases 0.000 claims description 5
• 206010002556 Ankylosing Spondylitis Diseases 0.000 claims description 5
• 206010006458 Bronchitis chronic Diseases 0.000 claims description 5
• 208000024172 Cardiovascular disease Diseases 0.000 claims description 5
• 206010009137 Chronic sinusitis Diseases 0.000 claims description 5
• 206010011224 Cough Diseases 0.000 claims description 5
• 201000003883 Cystic fibrosis Diseases 0.000 claims description 5
• 206010012438 Dermatitis atopic Diseases 0.000 claims description 5
• 206010014561 Emphysema Diseases 0.000 claims description 5
• 201000005569 Gout Diseases 0.000 claims description 5
• 208000019693 Lung disease Diseases 0.000 claims description 5
• 208000001145 Metabolic Syndrome Diseases 0.000 claims description 5
• 208000008589 Obesity Diseases 0.000 claims description 5
• 206010035664 Pneumonia Diseases 0.000 claims description 5
• 201000004681 Psoriasis Diseases 0.000 claims description 5
• 201000001263 Psoriatic Arthritis Diseases 0.000 claims description 5
• 208000036824 Psoriatic arthropathy Diseases 0.000 claims description 5
• 206010037423 Pulmonary oedema Diseases 0.000 claims description 5
• 206010039085 Rhinitis allergic Diseases 0.000 claims description 5
• 206010046851 Uveitis Diseases 0.000 claims description 5
• 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims description 5
• 201000010105 allergic rhinitis Diseases 0.000 claims description 5
• 208000006673 asthma Diseases 0.000 claims description 5
• 201000008937 atopic dermatitis Diseases 0.000 claims description 5
• 208000010668 atopic eczema Diseases 0.000 claims description 5
• 201000009267 bronchiectasis Diseases 0.000 claims description 5
• 206010006451 bronchitis Diseases 0.000 claims description 5
• 208000007451 chronic bronchitis Diseases 0.000 claims description 5
• 208000027157 chronic rhinosinusitis Diseases 0.000 claims description 5
• 201000001155 extrinsic allergic alveolitis Diseases 0.000 claims description 5
• 208000010706 fatty liver disease Diseases 0.000 claims description 5
• 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims description 5
• 208000022098 hypersensitivity pneumonitis Diseases 0.000 claims description 5
• 201000011486 lichen planus Diseases 0.000 claims description 5
• 208000030159 metabolic disease Diseases 0.000 claims description 5
• 230000003843 mucus production Effects 0.000 claims description 5
• 235000020824 obesity Nutrition 0.000 claims description 5
• 208000001797 obstructive sleep apnea Diseases 0.000 claims description 5
• 201000008482 osteoarthritis Diseases 0.000 claims description 5
• 125000002971 oxazolyl group Chemical group 0.000 claims description 5
• 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 5
• 208000005333 pulmonary edema Diseases 0.000 claims description 5
• 208000005069 pulmonary fibrosis Diseases 0.000 claims description 5
• 206010039073 rheumatoid arthritis Diseases 0.000 claims description 5
• 125000000335 thiazolyl group Chemical group 0.000 claims description 5
• 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 5
• 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 4
• 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 4
• 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 4
• 208000024827 Alzheimer disease Diseases 0.000 claims description 4
• 208000000044 Amnesia Diseases 0.000 claims description 4
• 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 4
• 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims description 4
• 206010009900 Colitis ulcerative Diseases 0.000 claims description 4
• 208000011231 Crohn disease Diseases 0.000 claims description 4
• 206010012289 Dementia Diseases 0.000 claims description 4
• 208000018522 Gastrointestinal disease Diseases 0.000 claims description 4
• 208000032612 Glial tumor Diseases 0.000 claims description 4
• 206010018338 Glioma Diseases 0.000 claims description 4
• 208000031226 Hyperlipidaemia Diseases 0.000 claims description 4
• 208000005615 Interstitial Cystitis Diseases 0.000 claims description 4
• 208000005777 Lupus Nephritis Diseases 0.000 claims description 4
• 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 4
• 208000026139 Memory disease Diseases 0.000 claims description 4
• 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims description 4
• 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 4
• 208000018737 Parkinson disease Diseases 0.000 claims description 4
• 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 4
• 208000004403 Prostatic Hyperplasia Diseases 0.000 claims description 4
• 206010056626 Pseudopolyp Diseases 0.000 claims description 4
• 206010039710 Scleroderma Diseases 0.000 claims description 4
• 208000006011 Stroke Diseases 0.000 claims description 4
• 201000009594 Systemic Scleroderma Diseases 0.000 claims description 4
• 206010042953 Systemic sclerosis Diseases 0.000 claims description 4
• 206010042971 T-cell lymphoma Diseases 0.000 claims description 4
• 201000006704 Ulcerative Colitis Diseases 0.000 claims description 4
• 208000038016 acute inflammation Diseases 0.000 claims description 4
• 230000006022 acute inflammation Effects 0.000 claims description 4
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 4
• 210000000013 bile duct Anatomy 0.000 claims description 4
• 208000025307 bipolar depression Diseases 0.000 claims description 4
• 208000037976 chronic inflammation Diseases 0.000 claims description 4
• 230000006020 chronic inflammation Effects 0.000 claims description 4
• 208000013507 chronic prostatitis Diseases 0.000 claims description 4
• 208000019425 cirrhosis of liver Diseases 0.000 claims description 4
• 125000000753 cycloalkyl group Chemical group 0.000 claims description 4
• 210000000232 gallbladder Anatomy 0.000 claims description 4
• 208000020123 juvenile polyp Diseases 0.000 claims description 4
• 230000006984 memory degeneration Effects 0.000 claims description 4
• 208000023060 memory loss Diseases 0.000 claims description 4
• 201000006417 multiple sclerosis Diseases 0.000 claims description 4
• 230000002093 peripheral effect Effects 0.000 claims description 4
• 201000007094 prostatitis Diseases 0.000 claims description 4
• 208000020016 psychiatric disease Diseases 0.000 claims description 4
• 201000000980 schizophrenia Diseases 0.000 claims description 4
• 238000001228 spectrum Methods 0.000 claims description 4
• 210000001835 viscera Anatomy 0.000 claims description 4
• 208000000884 Airway Obstruction Diseases 0.000 claims description 3
• 208000003950 B-cell lymphoma Diseases 0.000 claims description 3
• 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 claims description 3
• 208000037883 airway inflammation Diseases 0.000 claims description 3
• 230000002489 hematologic effect Effects 0.000 claims description 3
• 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 3
• 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 3
• 230000002062 proliferating effect Effects 0.000 claims description 3
• 239000012453 solvate Substances 0.000 claims description 3
• VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims description 2
• 239000005977 Ethylene Substances 0.000 claims description 2
• 208000015114 central nervous system disease Diseases 0.000 claims description 2
• 238000002156 mixing Methods 0.000 claims description 2
• 208000027232 peripheral nervous system disease Diseases 0.000 claims description 2
• 125000006526 (C1-C2) alkyl group Chemical group 0.000 claims 2
• 101100296720 Dictyostelium discoideum Pde4 gene Proteins 0.000 claims 1
• 101100082610 Plasmodium falciparum (isolate 3D7) PDEdelta gene Proteins 0.000 claims 1
• 125000001931 aliphatic group Chemical group 0.000 claims 1
• 125000002993 cycloalkylene group Chemical group 0.000 claims 1
• 230000003176 fibrotic effect Effects 0.000 claims 1
• 210000004392 genitalia Anatomy 0.000 claims 1
• 208000017443 reproductive system disease Diseases 0.000 claims 1
• 230000029058 respiratory gaseous exchange Effects 0.000 claims 1
• YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 231
• XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 228
• IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 130
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 129
• 239000007787 solid Substances 0.000 description 128
• 238000000034 method Methods 0.000 description 113
• 239000000243 solution Substances 0.000 description 106
• 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 103
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 88
• 239000011541 reaction mixture Substances 0.000 description 81
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 74
• 238000005160 1H NMR spectroscopy Methods 0.000 description 66
• 238000006243 chemical reaction Methods 0.000 description 65
• RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 64
• ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 63
• WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 50
• 239000012267 brine Substances 0.000 description 48
• HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 48
• 239000012044 organic layer Substances 0.000 description 43
• 238000010189 synthetic method Methods 0.000 description 39
• 239000002904 solvent Substances 0.000 description 37
• YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 33
• 239000011734 sodium Substances 0.000 description 33
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 31
• WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 30
• PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 29
• 239000000377 silicon dioxide Substances 0.000 description 29
• 229910052938 sodium sulfate Inorganic materials 0.000 description 25
• 235000011152 sodium sulphate Nutrition 0.000 description 25
• IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 24
• 239000010410 layer Substances 0.000 description 24
• ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 23
• 238000004440 column chromatography Methods 0.000 description 23
• 230000000694 effects Effects 0.000 description 22
• 238000002844 melting Methods 0.000 description 22
• 230000008018 melting Effects 0.000 description 22
• 238000000746 purification Methods 0.000 description 22
• YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 20
• 239000000047 product Substances 0.000 description 20
• BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 19
• 239000000741 silica gel Substances 0.000 description 19
• 229910002027 silica gel Inorganic materials 0.000 description 19
• 238000003818 flash chromatography Methods 0.000 description 18
• 239000012071 phase Substances 0.000 description 18
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 16
• 230000002829 reductive effect Effects 0.000 description 16
• UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 15
• VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 15
• 229910052731 fluorine Inorganic materials 0.000 description 14
• 239000003208 petroleum Substances 0.000 description 14
• 150000001732 carboxylic acid derivatives Chemical class 0.000 description 13
• 238000004809 thin layer chromatography Methods 0.000 description 13
• CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
• 238000005481 NMR spectroscopy Methods 0.000 description 12
• KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 12
• 108010037584 Type 4 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 description 12
• IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 12
• 229910000041 hydrogen chloride Inorganic materials 0.000 description 12
• 238000003756 stirring Methods 0.000 description 12
• RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 11
• NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 11
• XPGIBDJXEVAVTO-UHFFFAOYSA-N 5-bromo-2-chloropyrimidine Chemical compound ClC1=NC=C(Br)C=N1 XPGIBDJXEVAVTO-UHFFFAOYSA-N 0.000 description 11
• JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 11
• 239000000460 chlorine Substances 0.000 description 11
• 230000000875 corresponding effect Effects 0.000 description 11
• 238000001514 detection method Methods 0.000 description 11
• 239000000706 filtrate Substances 0.000 description 11
• 101000988424 Homo sapiens cAMP-specific 3',5'-cyclic phosphodiesterase 4B Proteins 0.000 description 10
• 238000006069 Suzuki reaction reaction Methods 0.000 description 10
• 102000011017 Type 4 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 description 10
• 125000001246 bromo group Chemical group Br* 0.000 description 10
• 229910052801 chlorine Inorganic materials 0.000 description 10
• 125000004093 cyano group Chemical group *C#N 0.000 description 10
• 229920000728 polyester Polymers 0.000 description 10
• BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 10
• 229920006395 saturated elastomer Polymers 0.000 description 10
• 239000000725 suspension Substances 0.000 description 10
• 230000001225 therapeutic effect Effects 0.000 description 10
• KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 9
• LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 9
• HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
• 150000001412 amines Chemical class 0.000 description 9
• 238000004458 analytical method Methods 0.000 description 9
• 239000002585 base Substances 0.000 description 9
• 238000005859 coupling reaction Methods 0.000 description 9
• WMFOQBRAJBCJND-UHFFFAOYSA-M lithium hydroxide Inorganic materials [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 9
• 150000003462 sulfoxides Chemical class 0.000 description 9
• 238000001308 synthesis method Methods 0.000 description 9
• 239000008346 aqueous phase Substances 0.000 description 8
• 239000012298 atmosphere Substances 0.000 description 8
• 102100029168 cAMP-specific 3',5'-cyclic phosphodiesterase 4B Human genes 0.000 description 8
• 229940079593 drug Drugs 0.000 description 8
• 150000002148 esters Chemical class 0.000 description 8
• 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 8
• 239000007789 gas Substances 0.000 description 8
• 239000007924 injection Substances 0.000 description 8
• 238000002347 injection Methods 0.000 description 8
• 238000010651 palladium-catalyzed cross coupling reaction Methods 0.000 description 8
• YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 8
• USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 7
• 239000005695 Ammonium acetate Substances 0.000 description 7
• KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 7
• 101150003085 Pdcl gene Proteins 0.000 description 7
• XWZXNTAOKAZULJ-UHFFFAOYSA-N [1-[5-(2-fluorophenyl)pyrimidin-2-yl]-3-methylindazol-6-yl]-morpholin-4-ylmethanone Chemical compound CC1=NN(C2=C1C=CC(=C2)C(=O)N1CCOCC1)C1=NC=C(C=N1)C1=C(F)C=CC=C1 XWZXNTAOKAZULJ-UHFFFAOYSA-N 0.000 description 7
• 235000019257 ammonium acetate Nutrition 0.000 description 7
• 229940043376 ammonium acetate Drugs 0.000 description 7
• PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 7
• 230000008878 coupling Effects 0.000 description 7
• 238000010168 coupling process Methods 0.000 description 7
• 239000003480 eluent Substances 0.000 description 7
• 238000001819 mass spectrum Methods 0.000 description 7
• MSYGAHOHLUJIKV-UHFFFAOYSA-N 3,5-dimethyl-1-(3-nitrophenyl)-1h-pyrazole-4-carboxylic acid ethyl ester Chemical compound CC1=C(C(=O)OCC)C(C)=NN1C1=CC=CC([N+]([O-])=O)=C1 MSYGAHOHLUJIKV-UHFFFAOYSA-N 0.000 description 6
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
• XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 6
• 238000001816 cooling Methods 0.000 description 6
• NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 6
• 125000005842 heteroatom Chemical group 0.000 description 6
• 238000004128 high performance liquid chromatography Methods 0.000 description 6
• 239000007800 oxidant agent Substances 0.000 description 6
• NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 6
• 239000002244 precipitate Substances 0.000 description 6
• 239000007921 spray Substances 0.000 description 6
• 239000000126 substance Substances 0.000 description 6
• 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 6
• NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 5
• 239000007821 HATU Substances 0.000 description 5
• MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 5
• KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 5
• 206010064911 Pulmonary arterial hypertension Diseases 0.000 description 5
• 238000006619 Stille reaction Methods 0.000 description 5
• DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 5
• 206010047700 Vomiting Diseases 0.000 description 5
• BBKPIIJWWBLKIC-UHFFFAOYSA-N [1-[5-(2-fluorophenyl)pyrimidin-2-yl]-3-methylsulfinylindazol-6-yl]-morpholin-4-ylmethanone Chemical compound CS(=O)C1=NN(C2=C1C=CC(=C2)C(=O)N1CCOCC1)C1=NC=C(C=N1)C1=C(F)C=CC=C1 BBKPIIJWWBLKIC-UHFFFAOYSA-N 0.000 description 5
• 239000004480 active ingredient Substances 0.000 description 5
• 239000012300 argon atmosphere Substances 0.000 description 5
• 125000003118 aryl group Chemical group 0.000 description 5
• 229910052794 bromium Inorganic materials 0.000 description 5
• 102100029170 cAMP-specific 3',5'-cyclic phosphodiesterase 4D Human genes 0.000 description 5
• 238000007257 deesterification reaction Methods 0.000 description 5
• 229910052740 iodine Inorganic materials 0.000 description 5
• 150000004702 methyl esters Chemical class 0.000 description 5
• BXGTVNLGPMZLAZ-UHFFFAOYSA-N n'-ethylmethanediimine;hydrochloride Chemical compound Cl.CCN=C=N BXGTVNLGPMZLAZ-UHFFFAOYSA-N 0.000 description 5
• 238000007254 oxidation reaction Methods 0.000 description 5
• 229910000027 potassium carbonate Inorganic materials 0.000 description 5
• 238000002360 preparation method Methods 0.000 description 5
• 230000000241 respiratory effect Effects 0.000 description 5
• 208000023504 respiratory system disease Diseases 0.000 description 5
• 239000007858 starting material Substances 0.000 description 5
• GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 4
• MSXVEPNJUHWQHW-UHFFFAOYSA-N 2-methylbutan-2-ol Chemical compound CCC(C)(C)O MSXVEPNJUHWQHW-UHFFFAOYSA-N 0.000 description 4
• VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
• ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 4
• 206010003210 Arteriosclerosis Diseases 0.000 description 4
• 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 4
• UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 4
• HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
• PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 4
• 241000282412 Homo Species 0.000 description 4
• 101000988419 Homo sapiens cAMP-specific 3',5'-cyclic phosphodiesterase 4D Proteins 0.000 description 4
• TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
• BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 4
• 206010028813 Nausea Diseases 0.000 description 4
• 229910002666 PdCl2 Inorganic materials 0.000 description 4
• OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 4
• JVQUZMLTFDRYBV-UHFFFAOYSA-N [1-[5-(2-fluorophenyl)pyrimidin-2-yl]-3-methylsulfinylindazol-6-yl]-piperazin-1-ylmethanone Chemical compound FC1=C(C=CC=C1)C=1C=NC(=NC=1)N1N=C(C2=CC=C(C=C12)C(=O)N1CCNCC1)S(=O)C JVQUZMLTFDRYBV-UHFFFAOYSA-N 0.000 description 4
• QAXXMJXJAJBJNK-UHFFFAOYSA-N [1-[5-(2-fluorophenyl)pyrimidin-2-yl]-3-methylsulfonylindazol-6-yl]-morpholin-4-ylmethanone Chemical compound FC1=C(C=CC=C1)C=1C=NC(=NC=1)N1N=C(C2=CC=C(C=C12)C(=O)N1CCOCC1)S(=O)(=O)C QAXXMJXJAJBJNK-UHFFFAOYSA-N 0.000 description 4
• 208000011775 arteriosclerosis disease Diseases 0.000 description 4
• ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 4
• 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 4
• 125000004432 carbon atom Chemical group C* 0.000 description 4
• 150000003857 carboxamides Chemical class 0.000 description 4
• 210000004027 cell Anatomy 0.000 description 4
• 239000011737 fluorine Substances 0.000 description 4
• 239000006260 foam Substances 0.000 description 4
• 150000002430 hydrocarbons Chemical group 0.000 description 4
• 230000004054 inflammatory process Effects 0.000 description 4
• 239000003112 inhibitor Substances 0.000 description 4
• 239000011630 iodine Substances 0.000 description 4
• 150000002500 ions Chemical class 0.000 description 4
• 238000005259 measurement Methods 0.000 description 4
• 230000008693 nausea Effects 0.000 description 4
• 230000003647 oxidation Effects 0.000 description 4
• PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 4
• SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 4
• 238000002953 preparative HPLC Methods 0.000 description 4
• MNDBXUUTURYVHR-UHFFFAOYSA-N roflumilast Chemical compound FC(F)OC1=CC=C(C(=O)NC=2C(=CN=CC=2Cl)Cl)C=C1OCC1CC1 MNDBXUUTURYVHR-UHFFFAOYSA-N 0.000 description 4
• 229960002586 roflumilast Drugs 0.000 description 4
• 238000010898 silica gel chromatography Methods 0.000 description 4
• LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 4
• 239000000758 substrate Substances 0.000 description 4
• 150000003457 sulfones Chemical class 0.000 description 4
• 238000001665 trituration Methods 0.000 description 4
• NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 3
• BJQCPCFFYBKRLM-UHFFFAOYSA-N (3-methylphenyl)boronic acid Chemical compound CC1=CC=CC(B(O)O)=C1 BJQCPCFFYBKRLM-UHFFFAOYSA-N 0.000 description 3
• 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 description 3
• BYEAHWXPCBROCE-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-ol Chemical compound FC(F)(F)C(O)C(F)(F)F BYEAHWXPCBROCE-UHFFFAOYSA-N 0.000 description 3
• BGDWZNJSHQBUKG-UHFFFAOYSA-N 1-[5-(2-fluorophenyl)pyrimidin-2-yl]-6-(morpholine-4-carbonyl)indazole-3-carboxamide Chemical compound FC1=C(C=CC=C1)C=1C=NC(=NC=1)N1N=C(C2=CC=C(C=C12)C(=O)N1CCOCC1)C(=O)N BGDWZNJSHQBUKG-UHFFFAOYSA-N 0.000 description 3
• 125000004066 1-hydroxyethyl group Chemical group [H]OC([H])([*])C([H])([H])[H] 0.000 description 3
• ZTHDGOABMVTBFB-UHFFFAOYSA-N 2-chloro-5-(2-fluorophenyl)pyrimidine Chemical compound FC1=CC=CC=C1C1=CN=C(Cl)N=C1 ZTHDGOABMVTBFB-UHFFFAOYSA-N 0.000 description 3
• 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 3
• 208000033962 Fontaine progeroid syndrome Diseases 0.000 description 3
• ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
• 239000012317 TBTU Substances 0.000 description 3
• MWTSYZBNZSIIDZ-UHFFFAOYSA-N [1-[5-(2-fluorophenyl)pyrimidin-2-yl]-3-methylsulfonylindazol-6-yl]-piperazin-1-ylmethanone Chemical compound FC1=C(C=CC=C1)C=1C=NC(=NC=1)N1N=C(C2=CC=C(C=C12)C(=O)N1CCNCC1)S(=O)(=O)C MWTSYZBNZSIIDZ-UHFFFAOYSA-N 0.000 description 3
• HWCKETMLDYZFFO-UHFFFAOYSA-N [3-cyclopropyl-1-[5-(2-fluorophenyl)pyrimidin-2-yl]indazol-6-yl]-morpholin-4-ylmethanone Chemical compound FC1=C(C=CC=C1)C1=CN=C(N=C1)N1N=C(C2CC2)C2=C1C=C(C=C2)C(=O)N1CCOCC1 HWCKETMLDYZFFO-UHFFFAOYSA-N 0.000 description 3
• 239000008186 active pharmaceutical agent Substances 0.000 description 3
• 230000002411 adverse Effects 0.000 description 3
• 125000003342 alkenyl group Chemical group 0.000 description 3
• 125000002947 alkylene group Chemical group 0.000 description 3
• 229910052786 argon Inorganic materials 0.000 description 3
• 230000008901 benefit Effects 0.000 description 3
• 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 3
• 239000012455 biphasic mixture Substances 0.000 description 3
• 239000003054 catalyst Substances 0.000 description 3
• 239000003795 chemical substances by application Substances 0.000 description 3
• 239000012043 crude product Substances 0.000 description 3
• 125000004966 cyanoalkyl group Chemical group 0.000 description 3
• 125000004122 cyclic group Chemical group 0.000 description 3
• 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 3
• 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 3
• 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 3
• UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 3
• 238000010931 ester hydrolysis Methods 0.000 description 3
• 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 3
• 125000004438 haloalkoxy group Chemical group 0.000 description 3
• 125000001188 haloalkyl group Chemical group 0.000 description 3
• 125000000623 heterocyclic group Chemical group 0.000 description 3
• 238000002868 homogeneous time resolved fluorescence Methods 0.000 description 3
• IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 3
• 125000004435 hydrogen atom Chemical group [H]* 0.000 description 3
• 230000003993 interaction Effects 0.000 description 3
• GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium;hydroxide;hydrate Chemical compound [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 3
• 239000000463 material Substances 0.000 description 3
• LCEDQNDDFOCWGG-UHFFFAOYSA-N morpholine-4-carbaldehyde Chemical compound O=CN1CCOCC1 LCEDQNDDFOCWGG-UHFFFAOYSA-N 0.000 description 3
• 208000037916 non-allergic rhinitis Diseases 0.000 description 3
• 239000012074 organic phase Substances 0.000 description 3
• 239000008194 pharmaceutical composition Substances 0.000 description 3
• 230000000144 pharmacologic effect Effects 0.000 description 3
• 229910052700 potassium Inorganic materials 0.000 description 3
• 239000011591 potassium Substances 0.000 description 3
• 238000012746 preparative thin layer chromatography Methods 0.000 description 3
• 230000002685 pulmonary effect Effects 0.000 description 3
• 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
• 235000017557 sodium bicarbonate Nutrition 0.000 description 3
• 238000012360 testing method Methods 0.000 description 3
• ZLODKAZZRDLUKX-UHFFFAOYSA-N (2-fluoro-5-methylphenyl)boronic acid Chemical compound CC1=CC=C(F)C(B(O)O)=C1 ZLODKAZZRDLUKX-UHFFFAOYSA-N 0.000 description 2
• 0 *c1ccccc1F Chemical compound *c1ccccc1F 0.000 description 2
• NCWDBNBNYVVARF-UHFFFAOYSA-N 1,3,2-dioxaborolane Chemical group B1OCCO1 NCWDBNBNYVVARF-UHFFFAOYSA-N 0.000 description 2
• LVEYOSJUKRVCCF-UHFFFAOYSA-N 1,3-bis(diphenylphosphino)propane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)CCCP(C=1C=CC=CC=1)C1=CC=CC=C1 LVEYOSJUKRVCCF-UHFFFAOYSA-N 0.000 description 2
• IMDRUWBVJAPHHZ-UHFFFAOYSA-N 1-[5-(2-fluoro-5-methylphenyl)pyrimidin-2-yl]-3-(1-hydroxyethyl)-N-(2-hydroxyethyl)-N-methylindazole-6-carboxamide Chemical compound FC1=C(C=C(C=C1)C)C=1C=NC(=NC=1)N1N=C(C2=CC=C(C=C12)C(=O)N(C)CCO)C(C)O IMDRUWBVJAPHHZ-UHFFFAOYSA-N 0.000 description 2
• GHTDODSYDCPOCW-UHFFFAOYSA-N 1h-indole-6-carboxylic acid Chemical compound OC(=O)C1=CC=C2C=CNC2=C1 GHTDODSYDCPOCW-UHFFFAOYSA-N 0.000 description 2
• QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
• YVKUHOXTHBIUPK-UHFFFAOYSA-N 2-chloro-5-(5-ethoxy-2-fluorophenyl)pyrimidine Chemical compound ClC1=NC=C(C=N1)C1=C(C=CC(=C1)OCC)F YVKUHOXTHBIUPK-UHFFFAOYSA-N 0.000 description 2
• UNCQVRBWJWWJBF-UHFFFAOYSA-N 2-chloropyrimidine Chemical compound ClC1=NC=CC=N1 UNCQVRBWJWWJBF-UHFFFAOYSA-N 0.000 description 2
• 102000001707 3',5'-Cyclic-AMP Phosphodiesterases Human genes 0.000 description 2
• 108010054479 3',5'-Cyclic-AMP Phosphodiesterases Proteins 0.000 description 2
• JDDHTPVGLIGJMM-UHFFFAOYSA-N 3-methylsulfanyl-1-(5-phenylpyrimidin-2-yl)indazole-6-carboxylic acid Chemical compound CSC1=NN(C2=C1C=CC(=C2)C(O)=O)C1=NC=C(C=N1)C1=CC=CC=C1 JDDHTPVGLIGJMM-UHFFFAOYSA-N 0.000 description 2
• UCFSYHMCKWNKAH-UHFFFAOYSA-N 4,4,5,5-tetramethyl-1,3,2-dioxaborolane Chemical compound CC1(C)OBOC1(C)C UCFSYHMCKWNKAH-UHFFFAOYSA-N 0.000 description 2
• DWOZNANUEDYIOF-UHFFFAOYSA-L 4-ditert-butylphosphanyl-n,n-dimethylaniline;dichloropalladium Chemical compound Cl[Pd]Cl.CN(C)C1=CC=C(P(C(C)(C)C)C(C)(C)C)C=C1.CN(C)C1=CC=C(P(C(C)(C)C)C(C)(C)C)C=C1 DWOZNANUEDYIOF-UHFFFAOYSA-L 0.000 description 2
• HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
• AEOBEOJCBAYXBA-UHFFFAOYSA-N A2P5P Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1OP(O)(O)=O AEOBEOJCBAYXBA-UHFFFAOYSA-N 0.000 description 2
• 206010002091 Anaesthesia Diseases 0.000 description 2
• WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
• MXXAXJIRPGZAPC-UHFFFAOYSA-N CSc1n[nH]c2cc(Br)ccc12 Chemical compound CSc1n[nH]c2cc(Br)ccc12 MXXAXJIRPGZAPC-UHFFFAOYSA-N 0.000 description 2
• ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
• 229910021595 Copper(I) iodide Inorganic materials 0.000 description 2
• 206010012735 Diarrhoea Diseases 0.000 description 2
• 206010061218 Inflammation Diseases 0.000 description 2
• 241000699670 Mus sp. Species 0.000 description 2
• JEKUEZZNDDWBQV-UHFFFAOYSA-N N-(2-amino-2-oxoethyl)-1-[5-(2-fluoro-5-methylsulfanylphenyl)pyrimidin-2-yl]-N,3-dimethylindazole-6-carboxamide Chemical compound CSC1=CC(=C(F)C=C1)C1=CN=C(N=C1)N1N=C(C)C2=C1C=C(C=C2)C(=O)N(C)CC(N)=O JEKUEZZNDDWBQV-UHFFFAOYSA-N 0.000 description 2
• LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
• SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 2
• OPKOKAMJFNKNAS-UHFFFAOYSA-N N-methylethanolamine Chemical compound CNCCO OPKOKAMJFNKNAS-UHFFFAOYSA-N 0.000 description 2
• ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
• 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 2
• 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 2
• CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 2
• HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
• IIYHSTNISNAORI-UHFFFAOYSA-N [1-(5-bromopyrimidin-2-yl)-3-methylsulfanylindazol-6-yl]-morpholin-4-ylmethanone Chemical compound CSC1=NN(C2=C1C=CC(=C2)C(=O)N1CCOCC1)C1=NC=C(Br)C=N1 IIYHSTNISNAORI-UHFFFAOYSA-N 0.000 description 2
• GWQJLCBWIAMEFM-UHFFFAOYSA-N [1-[5-(2-fluoro-5-methylphenyl)pyrimidin-2-yl]-3-methylsulfinylindazol-6-yl]-morpholin-4-ylmethanone Chemical compound FC1=C(C=C(C=C1)C)C=1C=NC(=NC=1)N1N=C(C2=CC=C(C=C12)C(=O)N1CCOCC1)S(=O)C GWQJLCBWIAMEFM-UHFFFAOYSA-N 0.000 description 2
• GDYBNUREHUHCMP-UHFFFAOYSA-N [1-[5-(2-fluorophenyl)pyrimidin-2-yl]-3-(trifluoromethyl)indazol-6-yl]-morpholin-4-ylmethanone Chemical compound FC1=C(C=CC=C1)C=1C=NC(=NC=1)N1N=C(C2=CC=C(C=C12)C(=O)N1CCOCC1)C(F)(F)F GDYBNUREHUHCMP-UHFFFAOYSA-N 0.000 description 2
• CLZISMQKJZCZDN-UHFFFAOYSA-N [benzotriazol-1-yloxy(dimethylamino)methylidene]-dimethylazanium Chemical compound C1=CC=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 CLZISMQKJZCZDN-UHFFFAOYSA-N 0.000 description 2
• 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 2
• UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 2
• 125000002723 alicyclic group Chemical group 0.000 description 2
• 125000000304 alkynyl group Chemical group 0.000 description 2
• 230000037005 anaesthesia Effects 0.000 description 2
• 230000001088 anti-asthma Effects 0.000 description 2
• 230000003110 anti-inflammatory effect Effects 0.000 description 2
• 239000000924 antiasthmatic agent Substances 0.000 description 2
• 238000003556 assay Methods 0.000 description 2
• 125000004429 atom Chemical group 0.000 description 2
• 230000003542 behavioural effect Effects 0.000 description 2
• HJKGBRPNSJADMB-UHFFFAOYSA-N beta-Phenylpyridine Natural products C1=CC=CC=C1C1=CC=CN=C1 HJKGBRPNSJADMB-UHFFFAOYSA-N 0.000 description 2
• 230000033228 biological regulation Effects 0.000 description 2
• 230000015572 biosynthetic process Effects 0.000 description 2
• ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 2
• GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
• 239000002775 capsule Substances 0.000 description 2
• 238000006835 carbomethoxylation reaction Methods 0.000 description 2
• 238000006555 catalytic reaction Methods 0.000 description 2
• 210000003169 central nervous system Anatomy 0.000 description 2
• 239000003153 chemical reaction reagent Substances 0.000 description 2
• 238000004296 chiral HPLC Methods 0.000 description 2
• 229940125782 compound 2 Drugs 0.000 description 2
• 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
• 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 2
• 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
• 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 2
• 238000012217 deletion Methods 0.000 description 2
• 230000037430 deletion Effects 0.000 description 2
• NKLCNNUWBJBICK-UHFFFAOYSA-N dess–martin periodinane Chemical compound C1=CC=C2I(OC(=O)C)(OC(C)=O)(OC(C)=O)OC(=O)C2=C1 NKLCNNUWBJBICK-UHFFFAOYSA-N 0.000 description 2
• 231100000673 dose–response relationship Toxicity 0.000 description 2
• 239000000975 dye Substances 0.000 description 2
• 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 2
• 230000000095 emetic effect Effects 0.000 description 2
• 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 description 2
• 238000001914 filtration Methods 0.000 description 2
• 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
• 239000008187 granular material Substances 0.000 description 2
• 150000004820 halides Chemical class 0.000 description 2
• 125000005843 halogen group Chemical group 0.000 description 2
• 238000000589 high-performance liquid chromatography-mass spectrometry Methods 0.000 description 2
• 150000002431 hydrogen Chemical class 0.000 description 2
• XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
• 125000002768 hydroxyalkyl group Chemical group 0.000 description 2
• NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 2
• 125000001041 indolyl group Chemical group 0.000 description 2
• 230000002757 inflammatory effect Effects 0.000 description 2
• 230000002401 inhibitory effect Effects 0.000 description 2
• 238000011835 investigation Methods 0.000 description 2
• 238000000752 ionisation method Methods 0.000 description 2
• 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
• 150000002576 ketones Chemical class 0.000 description 2
• 239000007788 liquid Substances 0.000 description 2
• 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 2
• 229910001629 magnesium chloride Inorganic materials 0.000 description 2
• 238000004949 mass spectrometry Methods 0.000 description 2
• 230000001404 mediated effect Effects 0.000 description 2
• ZDVOIENWYNGPPF-UHFFFAOYSA-N methyl 3-methylsulfanyl-1H-indazole-6-carboxylate Chemical compound COC(=O)C1=CC2=C(C=C1)C(SC)=NN2 ZDVOIENWYNGPPF-UHFFFAOYSA-N 0.000 description 2
• 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
• 239000003921 oil Substances 0.000 description 2
• 239000003960 organic solvent Substances 0.000 description 2
• YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 2
• 210000001428 peripheral nervous system Anatomy 0.000 description 2
• 125000001791 phenazinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3N=C12)* 0.000 description 2
• HXITXNWTGFUOAU-UHFFFAOYSA-N phenylboronic acid Chemical compound OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 description 2
• 235000011056 potassium acetate Nutrition 0.000 description 2
• 208000002815 pulmonary hypertension Diseases 0.000 description 2
• 125000003226 pyrazolyl group Chemical group 0.000 description 2
• 150000003254 radicals Chemical class 0.000 description 2
• 239000011535 reaction buffer Substances 0.000 description 2
• 238000010992 reflux Methods 0.000 description 2
• 210000002345 respiratory system Anatomy 0.000 description 2
• 208000017520 skin disease Diseases 0.000 description 2
• 235000010288 sodium nitrite Nutrition 0.000 description 2
• BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 2
• 238000004808 supercritical fluid chromatography Methods 0.000 description 2
• 238000003786 synthesis reaction Methods 0.000 description 2
• 239000006188 syrup Substances 0.000 description 2
• 235000020357 syrup Nutrition 0.000 description 2
• 239000003826 tablet Substances 0.000 description 2
• DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
• CWXPZXBSDSIRCS-UHFFFAOYSA-N tert-butyl piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCNCC1 CWXPZXBSDSIRCS-UHFFFAOYSA-N 0.000 description 2
• FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 2
• 150000003568 thioethers Chemical class 0.000 description 2
• 238000002877 time resolved fluorescence resonance energy transfer Methods 0.000 description 2
• 238000012546 transfer Methods 0.000 description 2
• ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 2
• 125000002827 triflate group Chemical group FC(S(=O)(=O)O*)(F)F 0.000 description 2
• JLTRXTDYQLMHGR-UHFFFAOYSA-N trimethylaluminium Chemical compound C[Al](C)C JLTRXTDYQLMHGR-UHFFFAOYSA-N 0.000 description 2
• 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
• 230000008673 vomiting Effects 0.000 description 2
• 238000005406 washing Methods 0.000 description 2
• CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 1
• QCSLIRFWJPOENV-UHFFFAOYSA-N (2-fluorophenyl)boronic acid Chemical compound OB(O)C1=CC=CC=C1F QCSLIRFWJPOENV-UHFFFAOYSA-N 0.000 description 1
• PDKBJYDGKRRHQA-UHFFFAOYSA-N (3-iodo-2H-indazol-6-yl)-morpholin-4-ylmethanone Chemical compound IC1=NNC2=CC(=CC=C12)C(=O)N1CCOCC1 PDKBJYDGKRRHQA-UHFFFAOYSA-N 0.000 description 1
• ITCSMTHUTFTXLE-UHFFFAOYSA-N (5-cyano-2-fluorophenyl)boronic acid Chemical compound OB(O)C1=CC(C#N)=CC=C1F ITCSMTHUTFTXLE-UHFFFAOYSA-N 0.000 description 1
• 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 1
• 125000006677 (C1-C3) haloalkoxy group Chemical group 0.000 description 1
• 125000006583 (C1-C3) haloalkyl group Chemical group 0.000 description 1
• 125000006699 (C1-C3) hydroxyalkyl group Chemical group 0.000 description 1
• 125000004767 (C1-C4) haloalkoxy group Chemical group 0.000 description 1
• 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 description 1
• 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 1
• PIRRWUMTIBFCCW-UHFFFAOYSA-N 1-(2-fluoro-4-methoxyphenyl)ethanone Chemical compound COC1=CC=C(C(C)=O)C(F)=C1 PIRRWUMTIBFCCW-UHFFFAOYSA-N 0.000 description 1
• ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
• VFOZTAVXRHGQSV-NSOVKSMOSA-N 1-N,2-N-bis[2-[(4R)-4-propan-2-yl-4,5-dihydro-1,3-oxazol-2-yl]phenyl]benzene-1,2-diamine Chemical compound C(C)(C)[C@H]1N=C(OC1)C1=C(C=CC=C1)NC=1C(=CC=CC=1)NC1=C(C=CC=C1)C=1OC[C@H](N=1)C(C)C VFOZTAVXRHGQSV-NSOVKSMOSA-N 0.000 description 1
• KQZLRWGGWXJPOS-NLFPWZOASA-N 1-[(1R)-1-(2,4-dichlorophenyl)ethyl]-6-[(4S,5R)-4-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-5-methylcyclohexen-1-yl]pyrazolo[3,4-b]pyrazine-3-carbonitrile Chemical compound ClC1=C(C=CC(=C1)Cl)[C@@H](C)N1N=C(C=2C1=NC(=CN=2)C1=CC[C@@H]([C@@H](C1)C)N1[C@@H](CCC1)CO)C#N KQZLRWGGWXJPOS-NLFPWZOASA-N 0.000 description 1
• QOVMDPZWYDMYIW-UHFFFAOYSA-N 1-[5-(2-fluoro-5-methylphenyl)pyrimidin-2-yl]-3-(1-hydroxyethyl)indazole-6-carboxylic acid Chemical compound CC(O)C1=NN(C2=C1C=CC(=C2)C(O)=O)C1=NC=C(C=N1)C1=C(F)C=CC(C)=C1 QOVMDPZWYDMYIW-UHFFFAOYSA-N 0.000 description 1
• 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
• LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
• FPIRBHDGWMWJEP-UHFFFAOYSA-N 1-hydroxy-7-azabenzotriazole Chemical compound C1=CN=C2N(O)N=NC2=C1 FPIRBHDGWMWJEP-UHFFFAOYSA-N 0.000 description 1
• PJUPKRYGDFTMTM-UHFFFAOYSA-N 1-hydroxybenzotriazole;hydrate Chemical compound O.C1=CC=C2N(O)N=NC2=C1 PJUPKRYGDFTMTM-UHFFFAOYSA-N 0.000 description 1
• KMRWHESBJZFGFH-UHFFFAOYSA-N 1-methylpiperazin-2-one;hydrochloride Chemical compound Cl.CN1CCNCC1=O KMRWHESBJZFGFH-UHFFFAOYSA-N 0.000 description 1
• DLIXYDCDIXUKNQ-UHFFFAOYSA-N 1-o-tert-butyl 6-o-methyl 3-iodoindazole-1,6-dicarboxylate Chemical compound COC(=O)C1=CC=C2C(I)=NN(C(=O)OC(C)(C)C)C2=C1 DLIXYDCDIXUKNQ-UHFFFAOYSA-N 0.000 description 1
• 101150000874 11 gene Proteins 0.000 description 1
• CPLJDNFVGMXJLO-UHFFFAOYSA-N 1h-indol-6-yl(morpholin-4-yl)methanone Chemical compound C=1C=C2C=CNC2=CC=1C(=O)N1CCOCC1 CPLJDNFVGMXJLO-UHFFFAOYSA-N 0.000 description 1
• KJLFFCRGGGXQKE-UHFFFAOYSA-N 1h-indole-6-carboxamide Chemical compound NC(=O)C1=CC=C2C=CNC2=C1 KJLFFCRGGGXQKE-UHFFFAOYSA-N 0.000 description 1
• ZNOVTXRBGFNYRX-UHFFFAOYSA-N 2-[[4-[(2-amino-5-methyl-4-oxo-1,6,7,8-tetrahydropteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 ZNOVTXRBGFNYRX-UHFFFAOYSA-N 0.000 description 1
• LSZMVESSGLHDJE-UHFFFAOYSA-N 2-bromo-4-methylpyridine Chemical compound CC1=CC=NC(Br)=C1 LSZMVESSGLHDJE-UHFFFAOYSA-N 0.000 description 1
• 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
• JJNIWMPNOFGQEA-UHFFFAOYSA-N 2-chloro-5-phenylpyrimidine Chemical compound C1=NC(Cl)=NC=C1C1=CC=CC=C1 JJNIWMPNOFGQEA-UHFFFAOYSA-N 0.000 description 1
• QKHVYVWUZZAQBC-UHFFFAOYSA-N 2-chloro-5-pyridin-2-ylpyrimidine Chemical compound C1=NC(Cl)=NC=C1C1=CC=CC=N1 QKHVYVWUZZAQBC-UHFFFAOYSA-N 0.000 description 1
• 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
• 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
• 125000005916 2-methylpentyl group Chemical group 0.000 description 1
• 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
• APIXJSLKIYYUKG-UHFFFAOYSA-N 3 Isobutyl 1 methylxanthine Chemical compound O=C1N(C)C(=O)N(CC(C)C)C2=C1N=CN2 APIXJSLKIYYUKG-UHFFFAOYSA-N 0.000 description 1
• ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 1
• FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
• 125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 description 1
• YHDZQEMQOVZPIH-UHFFFAOYSA-N 3-cyclopropyl-1-(5-phenylpyrimidin-2-yl)indazole-6-carboxylic acid Chemical compound OC(=O)C1=CC2=C(C=C1)C(=NN2C1=NC=C(C=N1)C1=CC=CC=C1)C1CC1 YHDZQEMQOVZPIH-UHFFFAOYSA-N 0.000 description 1
• WIDRSYUOIUJONG-UHFFFAOYSA-N 3-cyclopropyl-1-[5-(5-ethoxy-2-fluorophenyl)pyrimidin-2-yl]indazole-6-carboxylic acid Chemical compound C1(CC1)C1=NN(C2=CC(=CC=C12)C(=O)O)C1=NC=C(C=N1)C1=C(C=CC(=C1)OCC)F WIDRSYUOIUJONG-UHFFFAOYSA-N 0.000 description 1
• HSRKNZOHAZLZKQ-UHFFFAOYSA-N 3-formyl-2h-indazole-6-carboxylic acid Chemical compound OC(=O)C1=CC=C2C(C=O)=NNC2=C1 HSRKNZOHAZLZKQ-UHFFFAOYSA-N 0.000 description 1
• UDKYMMQGPNFWDA-UHFFFAOYSA-N 3-iodo-2h-indazole Chemical compound C1=CC=CC2=C(I)NN=C21 UDKYMMQGPNFWDA-UHFFFAOYSA-N 0.000 description 1
• 125000003542 3-methylbutan-2-yl group Chemical group [H]C([H])([H])C([H])(*)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• 125000005917 3-methylpentyl group Chemical group 0.000 description 1
• 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
• 125000001845 4 membered carbocyclic group Chemical group 0.000 description 1
• UPCARQPLANFGQJ-UHFFFAOYSA-N 4-bromo-2-fluorobenzaldehyde Chemical compound FC1=CC(Br)=CC=C1C=O UPCARQPLANFGQJ-UHFFFAOYSA-N 0.000 description 1
• PUZJORWYNXKVME-UHFFFAOYSA-N 4-fluoro-3-[2-[3-methylsulfinyl-6-(morpholine-4-carbonyl)indazol-1-yl]pyrimidin-5-yl]benzonitrile Chemical compound FC1=C(C=C(C#N)C=C1)C=1C=NC(=NC=1)N1N=C(C2=CC=C(C=C12)C(=O)N1CCOCC1)S(=O)C PUZJORWYNXKVME-UHFFFAOYSA-N 0.000 description 1
• SJZSAEHQJBWBNS-UHFFFAOYSA-N 4-fluoro-3-[2-[3-methylsulfonyl-6-(morpholine-4-carbonyl)indazol-1-yl]pyrimidin-5-yl]benzonitrile Chemical compound FC1=C(C=C(C#N)C=C1)C=1C=NC(=NC=1)N1N=C(C2=CC=C(C=C12)C(=O)N1CCOCC1)S(=O)(=O)C SJZSAEHQJBWBNS-UHFFFAOYSA-N 0.000 description 1
• 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
• 125000001054 5 membered carbocyclic group Chemical group 0.000 description 1
• UPJKSWLLCONYMW-UHFFFAOYSA-N 5'-Adenosine monophosphate Natural products COc1cc(O)c(C(=O)C)c(OC2OC(COC3OC(C)C(O)C(O)C3O)C(O)C(O)C2O)c1 UPJKSWLLCONYMW-UHFFFAOYSA-N 0.000 description 1
• MVXAKOGJWVQPKC-UHFFFAOYSA-N 5-(3-ethynyl-5-fluorophenyl)-2-pyridin-2-yl-4,6,7,8-tetrahydro-[1,3]oxazolo[4,5-c]azepine Chemical compound FC1=CC(C#C)=CC(N2CC=3N=C(OC=3CCC2)C=2N=CC=CC=2)=C1 MVXAKOGJWVQPKC-UHFFFAOYSA-N 0.000 description 1
• LVXOXXGCJHYEOS-UHFFFAOYSA-N 5-phenylpyrimidine Chemical compound C1=CC=CC=C1C1=CN=CN=C1 LVXOXXGCJHYEOS-UHFFFAOYSA-N 0.000 description 1
• 125000004008 6 membered carbocyclic group Chemical group 0.000 description 1
• OOTXIASGIQGKSJ-UHFFFAOYSA-N 6-(morpholine-4-carbonyl)-2H-indazole-3-carbaldehyde Chemical compound N1(CCOCC1)C(=O)C1=CC=C2C(=NNC2=C1)C=O OOTXIASGIQGKSJ-UHFFFAOYSA-N 0.000 description 1
• WMKDUJVLNZANRN-UHFFFAOYSA-N 6-bromo-1h-indazole Chemical compound BrC1=CC=C2C=NNC2=C1 WMKDUJVLNZANRN-UHFFFAOYSA-N 0.000 description 1
• 125000001960 7 membered carbocyclic group Chemical group 0.000 description 1
• NQGGATBMOWJYGE-UHFFFAOYSA-N C1CC1C2=NN(C3=C2C=CC(=C3)C(=O)N4CCN(C(=O)C4)C(=O)O)C5=NC=C(C=N5)C6=CC=CC=C6 Chemical compound C1CC1C2=NN(C3=C2C=CC(=C3)C(=O)N4CCN(C(=O)C4)C(=O)O)C5=NC=C(C=N5)C6=CC=CC=C6 NQGGATBMOWJYGE-UHFFFAOYSA-N 0.000 description 1
• HLEPDWSFHKSEIW-UHFFFAOYSA-N C=[Br]c1ccc(C(I)=N)c(N)c1 Chemical compound C=[Br]c1ccc(C(I)=N)c(N)c1 HLEPDWSFHKSEIW-UHFFFAOYSA-N 0.000 description 1
• YTVYOJSWGWFCEN-UHFFFAOYSA-N CSc(c(c1c2)ccc2Br)n[n]1-c(nc1)ncc1-c1ccccc1F Chemical compound CSc(c(c1c2)ccc2Br)n[n]1-c(nc1)ncc1-c1ccccc1F YTVYOJSWGWFCEN-UHFFFAOYSA-N 0.000 description 1
• VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
• UDMBCSSLTHHNCD-UHFFFAOYSA-N Coenzym Q(11) Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1O UDMBCSSLTHHNCD-UHFFFAOYSA-N 0.000 description 1
• IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 1
• 206010048768 Dermatosis Diseases 0.000 description 1
• 229910052693 Europium Inorganic materials 0.000 description 1
• 208000001860 Eye Infections Diseases 0.000 description 1
• YNFMOAIXQYPMME-UHFFFAOYSA-N Fc1ccccc1-c1c[nH]nc1 Chemical compound Fc1ccccc1-c1c[nH]nc1 YNFMOAIXQYPMME-UHFFFAOYSA-N 0.000 description 1
• 238000003747 Grignard reaction Methods 0.000 description 1
• IVDFJHOHABJVEH-UHFFFAOYSA-N HOCMe2CMe2OH Natural products CC(C)(O)C(C)(C)O IVDFJHOHABJVEH-UHFFFAOYSA-N 0.000 description 1
• 206010019233 Headaches Diseases 0.000 description 1
• 101000610640 Homo sapiens U4/U6 small nuclear ribonucleoprotein Prp3 Proteins 0.000 description 1
• 101001098805 Homo sapiens cAMP-specific 3',5'-cyclic phosphodiesterase 4A Proteins 0.000 description 1
• 101000988423 Homo sapiens cAMP-specific 3',5'-cyclic phosphodiesterase 4C Proteins 0.000 description 1
• 108010044467 Isoenzymes Proteins 0.000 description 1
• WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
• 239000012448 Lithium borohydride Substances 0.000 description 1
• 206010025323 Lymphomas Diseases 0.000 description 1
• 241000124008 Mammalia Species 0.000 description 1
• LBSPPHUYZVDXAE-UHFFFAOYSA-N N-(2-amino-2-oxoethyl)-1-[5-(2-fluoro-5-methylphenyl)pyrimidin-2-yl]-3-(1-hydroxyethyl)-N-methylindazole-6-carboxamide Chemical compound NC(CN(C(=O)C1=CC=C2C(=NN(C2=C1)C1=NC=C(C=N1)C1=C(C=CC(=C1)C)F)C(C)O)C)=O LBSPPHUYZVDXAE-UHFFFAOYSA-N 0.000 description 1
• ODBFWEXWGDUMCB-UHFFFAOYSA-N N-(2-amino-2-oxoethyl)-1-[5-(2-fluoro-5-methylsulfinylphenyl)pyrimidin-2-yl]-N,3-dimethylindazole-6-carboxamide Chemical compound NC(CN(C(=O)C1=CC=C2C(=NN(C2=C1)C1=NC=C(C=N1)C1=C(C=CC(=C1)S(=O)C)F)C)C)=O ODBFWEXWGDUMCB-UHFFFAOYSA-N 0.000 description 1
• UYTOOULUZDISID-UHFFFAOYSA-N N-(2-amino-2-oxoethyl)-1-[5-(2-fluoro-5-methylsulfonylphenyl)pyrimidin-2-yl]-N,3-dimethylindazole-6-carboxamide Chemical compound NC(CN(C(=O)C1=CC=C2C(=NN(C2=C1)C1=NC=C(C=N1)C1=C(C=CC(=C1)S(=O)(=O)C)F)C)C)=O UYTOOULUZDISID-UHFFFAOYSA-N 0.000 description 1
• XOEVKJUUEGMABH-UHFFFAOYSA-N N-(2-amino-2-oxoethyl)-1-[5-(5-ethoxy-2-fluorophenyl)pyrimidin-2-yl]-N,3-dimethylindazole-6-carboxamide Chemical compound NC(CN(C(=O)C1=CC=C2C(=NN(C2=C1)C1=NC=C(C=N1)C1=C(C=CC(=C1)OCC)F)C)C)=O XOEVKJUUEGMABH-UHFFFAOYSA-N 0.000 description 1
• CVJKYBDLTDAGKM-UHFFFAOYSA-N N-(2-amino-2-oxoethyl)-1-[5-(5-ethyl-2-fluorophenyl)pyrimidin-2-yl]-3-(1-hydroxyethyl)-N-methylindazole-6-carboxamide Chemical compound NC(CN(C(=O)C1=CC=C2C(=NN(C2=C1)C1=NC=C(C=N1)C1=C(C=CC(=C1)CC)F)C(C)O)C)=O CVJKYBDLTDAGKM-UHFFFAOYSA-N 0.000 description 1
• ZBRRDHOHXQMTJC-UHFFFAOYSA-N N-(2-amino-2-oxoethyl)-1-[5-[2-fluoro-5-(1-hydroxyethyl)phenyl]pyrimidin-2-yl]-N,3-dimethylindazole-6-carboxamide Chemical compound CC(O)C1=CC(=C(F)C=C1)C1=CN=C(N=C1)N1N=C(C)C2=C1C=C(C=C2)C(=O)N(C)CC(N)=O ZBRRDHOHXQMTJC-UHFFFAOYSA-N 0.000 description 1
• KWZXFQPSQBAYMC-UHFFFAOYSA-N N-(2-amino-2-oxoethyl)-1-[5-[2-fluoro-5-(2-hydroxypropan-2-yl)phenyl]pyrimidin-2-yl]-N,3-dimethylindazole-6-carboxamide Chemical compound NC(CN(C(=O)C1=CC=C2C(=NN(C2=C1)C1=NC=C(C=N1)C1=C(C=CC(=C1)C(C)(C)O)F)C)C)=O KWZXFQPSQBAYMC-UHFFFAOYSA-N 0.000 description 1
• HPLVCWGGDQFOJS-UHFFFAOYSA-N N-(2-amino-2-oxoethyl)-3-cyclopropyl-1-[5-(2-fluoro-5-methylsulfinylphenyl)pyrimidin-2-yl]-N-methylindazole-6-carboxamide Chemical compound NC(CN(C(=O)C1=CC=C2C(=NN(C2=C1)C1=NC=C(C=N1)C1=C(C=CC(=C1)S(=O)C)F)C1CC1)C)=O HPLVCWGGDQFOJS-UHFFFAOYSA-N 0.000 description 1
• OJPVWRNAUDTSCV-UHFFFAOYSA-N N-(2-amino-2-oxoethyl)-3-cyclopropyl-1-[5-(2-fluoro-5-methylsulfonylphenyl)pyrimidin-2-yl]-N-methylindazole-6-carboxamide Chemical compound NC(CN(C(=O)C1=CC=C2C(=NN(C2=C1)C1=NC=C(C=N1)C1=C(C=CC(=C1)S(=O)(=O)C)F)C1CC1)C)=O OJPVWRNAUDTSCV-UHFFFAOYSA-N 0.000 description 1
• IUEYJUGPTJGXQH-UHFFFAOYSA-N N-(2-amino-2-oxoethyl)-3-cyclopropyl-1-[5-(5-ethoxy-2-fluorophenyl)pyrimidin-2-yl]-N-methylindazole-6-carboxamide Chemical compound NC(CN(C(=O)C1=CC=C2C(=NN(C2=C1)C1=NC=C(C=N1)C1=C(C=CC(=C1)OCC)F)C1CC1)C)=O IUEYJUGPTJGXQH-UHFFFAOYSA-N 0.000 description 1
• PNSFBOITMLEQRD-UHFFFAOYSA-N N-(2-amino-2-oxoethyl)-3-cyclopropyl-1-[5-[2-fluoro-5-(1-hydroxyethyl)phenyl]pyrimidin-2-yl]-N-methylindazole-6-carboxamide Chemical compound NC(CN(C(=O)C1=CC=C2C(=NN(C2=C1)C1=NC=C(C=N1)C1=C(C=CC(=C1)C(C)O)F)C1CC1)C)=O PNSFBOITMLEQRD-UHFFFAOYSA-N 0.000 description 1
• SZAROUHYTMSCTQ-UHFFFAOYSA-N N-(2-amino-2-oxoethyl)-3-cyclopropyl-1-[5-[2-fluoro-5-(2-hydroxypropan-2-yl)phenyl]pyrimidin-2-yl]-N-methylindazole-6-carboxamide Chemical compound NC(CN(C(=O)C1=CC=C2C(=NN(C2=C1)C1=NC=C(C=N1)C1=C(C=CC(=C1)C(C)(C)O)F)C1CC1)C)=O SZAROUHYTMSCTQ-UHFFFAOYSA-N 0.000 description 1
• PAYRUJLWNCNPSJ-UHFFFAOYSA-N N-phenyl amine Natural products NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 1
• IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 1
• 229910019142 PO4 Inorganic materials 0.000 description 1
• 229940099471 Phosphodiesterase inhibitor Drugs 0.000 description 1
• 229920001213 Polysorbate 20 Polymers 0.000 description 1
• 108010029485 Protein Isoforms Proteins 0.000 description 1
• 102000001708 Protein Isoforms Human genes 0.000 description 1
• YZCKVEUIGOORGS-IGMARMGPSA-N Protium Chemical compound [1H] YZCKVEUIGOORGS-IGMARMGPSA-N 0.000 description 1
• 101001110823 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 60S ribosomal protein L6-A Proteins 0.000 description 1
• 101000712176 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 60S ribosomal protein L6-B Proteins 0.000 description 1
• 229940124639 Selective inhibitor Drugs 0.000 description 1
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
• UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 1
• 102100040374 U4/U6 small nuclear ribonucleoprotein Prp3 Human genes 0.000 description 1
• OTOABCRHHODUEW-UHFFFAOYSA-N [1-(5-bromopyrimidin-2-yl)-3-(1-hydroxyethyl)indazol-6-yl]-morpholin-4-ylmethanone Chemical compound CC(O)C1=NN(C2=C1C=CC(=C2)C(=O)N1CCOCC1)C1=NC=C(Br)C=N1 OTOABCRHHODUEW-UHFFFAOYSA-N 0.000 description 1
• PXTZHNYNCATHLB-UHFFFAOYSA-N [1-(5-bromopyrimidin-2-yl)-3-methylsulfinylindazol-6-yl]-morpholin-4-ylmethanone Chemical compound BrC=1C=NC(=NC=1)N1N=C(C2=CC=C(C=C12)C(=O)N1CCOCC1)S(=O)C PXTZHNYNCATHLB-UHFFFAOYSA-N 0.000 description 1
• GJYZPQCXVYGBRI-UHFFFAOYSA-N [1-[5-(2-fluoro-5-methoxyphenyl)pyrimidin-2-yl]-3-(1-hydroxyethyl)indazol-6-yl]-morpholin-4-ylmethanone Chemical compound FC1=C(C=C(C=C1)OC)C=1C=NC(=NC=1)N1N=C(C2=CC=C(C=C12)C(=O)N1CCOCC1)C(C)O GJYZPQCXVYGBRI-UHFFFAOYSA-N 0.000 description 1
• GBLQSJRJWQWPKH-UHFFFAOYSA-N [1-[5-(2-fluoro-5-methoxyphenyl)pyrimidin-2-yl]-3-methylsulfinylindazol-6-yl]-morpholin-4-ylmethanone Chemical compound FC1=C(C=C(C=C1)OC)C=1C=NC(=NC=1)N1N=C(C2=CC=C(C=C12)C(=O)N1CCOCC1)S(=O)C GBLQSJRJWQWPKH-UHFFFAOYSA-N 0.000 description 1
• OZNBQBYRXGXMPB-UHFFFAOYSA-N [1-[5-(2-fluoro-5-methoxyphenyl)pyrimidin-2-yl]-3-methylsulfonylindazol-6-yl]-morpholin-4-ylmethanone Chemical compound FC1=C(C=C(C=C1)OC)C=1C=NC(=NC=1)N1N=C(C2=CC=C(C=C12)C(=O)N1CCOCC1)S(=O)(=O)C OZNBQBYRXGXMPB-UHFFFAOYSA-N 0.000 description 1
• KYOQXBBSVZSOHM-UHFFFAOYSA-N [1-[5-(2-fluoro-5-methylphenyl)pyrimidin-2-yl]-3-methylsulfonylindazol-6-yl]-morpholin-4-ylmethanone Chemical compound FC1=C(C=C(C=C1)C)C=1C=NC(=NC=1)N1N=C(C2=CC=C(C=C12)C(=O)N1CCOCC1)S(=O)(=O)C KYOQXBBSVZSOHM-UHFFFAOYSA-N 0.000 description 1
• RVOJEFZRSUSPCG-UHFFFAOYSA-N [1-[5-(2-fluorophenyl)pyrimidin-2-yl]-3-(1-hydroxyethyl)indazol-6-yl]-morpholin-4-ylmethanone Chemical compound FC1=C(C=CC=C1)C=1C=NC(=NC=1)N1N=C(C2=CC=C(C=C12)C(=O)N1CCOCC1)C(C)O RVOJEFZRSUSPCG-UHFFFAOYSA-N 0.000 description 1
• UEWYILJHJZCDSS-UHFFFAOYSA-N [1-[5-(2-fluorophenyl)pyrimidin-2-yl]-3-(2-hydroxypropan-2-yl)indazol-6-yl]-morpholin-4-ylmethanone Chemical compound FC1=C(C=CC=C1)C=1C=NC(=NC=1)N1N=C(C2=CC=C(C=C12)C(=O)N1CCOCC1)C(C)(C)O UEWYILJHJZCDSS-UHFFFAOYSA-N 0.000 description 1
• SEOGGZXWXWMDAP-UHFFFAOYSA-N [1-[5-(3-cyclopropylphenyl)pyrimidin-2-yl]-3-(1-hydroxyethyl)indazol-6-yl]-morpholin-4-ylmethanone Chemical compound C1(CC1)C=1C=C(C=CC=1)C=1C=NC(=NC=1)N1N=C(C2=CC=C(C=C12)C(=O)N1CCOCC1)C(C)O SEOGGZXWXWMDAP-UHFFFAOYSA-N 0.000 description 1
• VJIHBXMOCAYCFV-UHFFFAOYSA-N [1-[5-(3-cyclopropylphenyl)pyrimidin-2-yl]-3-methylsulfinylindazol-6-yl]-morpholin-4-ylmethanone Chemical compound C1(CC1)C=1C=C(C=CC=1)C=1C=NC(=NC=1)N1N=C(C2=CC=C(C=C12)C(=O)N1CCOCC1)S(=O)C VJIHBXMOCAYCFV-UHFFFAOYSA-N 0.000 description 1
• LROCKLXFJZOMQP-UHFFFAOYSA-N [1-[5-(3-methylphenyl)pyrimidin-2-yl]-3-methylsulfinylindazol-6-yl]-morpholin-4-ylmethanone Chemical compound CC1=CC=CC(=C1)C1=CN=C(N=C1)N1N=C(C2=C1C=C(C=C2)C(=O)N1CCOCC1)S(C)=O LROCKLXFJZOMQP-UHFFFAOYSA-N 0.000 description 1
• XFNHAPTVHLBOPT-UHFFFAOYSA-N [1-[5-(3-methylphenyl)pyrimidin-2-yl]-3-methylsulfonylindazol-6-yl]-morpholin-4-ylmethanone Chemical compound CS(=O)(=O)C1=NN(C2=CC(=CC=C12)C(=O)N1CCOCC1)C1=NC=C(C=N1)C=1C=C(C=CC=1)C XFNHAPTVHLBOPT-UHFFFAOYSA-N 0.000 description 1
• XMULBEYGIYDGRE-UHFFFAOYSA-N [1-[5-(4-cyclopropylpyridin-2-yl)pyrimidin-2-yl]-3-(1-hydroxyethyl)indazol-6-yl]-morpholin-4-ylmethanone Chemical compound C1(CC1)C1=CC(=NC=C1)C=1C=NC(=NC=1)N1N=C(C2=CC=C(C=C12)C(=O)N1CCOCC1)C(C)O XMULBEYGIYDGRE-UHFFFAOYSA-N 0.000 description 1
• SIORPZSBDLCUCJ-UHFFFAOYSA-N [1-[5-(4-cyclopropylpyridin-2-yl)pyrimidin-2-yl]-3-methylsulfinylindazol-6-yl]-morpholin-4-ylmethanone Chemical compound C1(CC1)C1=CC(=NC=C1)C=1C=NC(=NC=1)N1N=C(C2=CC=C(C=C12)C(=O)N1CCOCC1)S(=O)C SIORPZSBDLCUCJ-UHFFFAOYSA-N 0.000 description 1
• ZTRLRFNFIAHEHG-UHFFFAOYSA-N [1-[5-(4-ethylpyridin-2-yl)pyrimidin-2-yl]-3-(1-hydroxyethyl)indazol-6-yl]-morpholin-4-ylmethanone Chemical compound C(C)C1=CC(=NC=C1)C=1C=NC(=NC=1)N1N=C(C2=CC=C(C=C12)C(=O)N1CCOCC1)C(C)O ZTRLRFNFIAHEHG-UHFFFAOYSA-N 0.000 description 1
• NPWCETIWIVEQQA-UHFFFAOYSA-N [1-[5-(4-methoxypyridin-2-yl)pyrimidin-2-yl]-3-methylsulfinylindazol-6-yl]-morpholin-4-ylmethanone Chemical compound COC1=CC(=NC=C1)C=1C=NC(=NC=1)N1N=C(C2=CC=C(C=C12)C(=O)N1CCOCC1)S(=O)C NPWCETIWIVEQQA-UHFFFAOYSA-N 0.000 description 1
• IFVDWXFWYCVQLD-UHFFFAOYSA-N [1-[5-(4-methylpyridin-2-yl)pyrimidin-2-yl]-3-methylsulfinylindazol-6-yl]-morpholin-4-ylmethanone Chemical compound CC1=CC(=NC=C1)C=1C=NC(=NC=1)N1N=C(C2=CC=C(C=C12)C(=O)N1CCOCC1)S(=O)C IFVDWXFWYCVQLD-UHFFFAOYSA-N 0.000 description 1
• CAHPMRFIXIYJOX-UHFFFAOYSA-N [1-[5-(5-cyclopropyl-2-fluorophenyl)pyrimidin-2-yl]-3-(1-hydroxyethyl)indazol-6-yl]-morpholin-4-ylmethanone Chemical compound C1(CC1)C=1C=CC(=C(C=1)C=1C=NC(=NC=1)N1N=C(C2=CC=C(C=C12)C(=O)N1CCOCC1)C(C)O)F CAHPMRFIXIYJOX-UHFFFAOYSA-N 0.000 description 1
• OEFFCRDDQKYNTJ-UHFFFAOYSA-N [1-[5-(5-ethoxy-2-fluorophenyl)pyrimidin-2-yl]-3-(1-hydroxyethyl)indazol-6-yl]-morpholin-4-ylmethanone Chemical compound C(C)OC=1C=CC(=C(C=1)C=1C=NC(=NC=1)N1N=C(C2=CC=C(C=C12)C(=O)N1CCOCC1)C(C)O)F OEFFCRDDQKYNTJ-UHFFFAOYSA-N 0.000 description 1
• GDQUBWOSKRHJGD-UHFFFAOYSA-N [3-(1-hydroxyethyl)-1-(5-phenylpyrimidin-2-yl)indazol-6-yl]-morpholin-4-ylmethanone Chemical compound OC(C)C1=NN(C2=CC(=CC=C12)C(=O)N1CCOCC1)C1=NC=C(C=N1)C1=CC=CC=C1 GDQUBWOSKRHJGD-UHFFFAOYSA-N 0.000 description 1
• VGBFQOSENVVXJM-UHFFFAOYSA-N [3-(1-hydroxyethyl)-1-[5-(3-methylphenyl)pyrimidin-2-yl]indazol-6-yl]-morpholin-4-ylmethanone Chemical compound OC(C)C1=NN(C2=CC(=CC=C12)C(=O)N1CCOCC1)C1=NC=C(C=N1)C=1C=C(C=CC=1)C VGBFQOSENVVXJM-UHFFFAOYSA-N 0.000 description 1
• RHHQNPCKCPVJAV-UHFFFAOYSA-N [3-(1-hydroxyethyl)-1-[5-(4-methoxypyridin-2-yl)pyrimidin-2-yl]indazol-6-yl]-morpholin-4-ylmethanone Chemical compound OC(C)C1=NN(C2=CC(=CC=C12)C(=O)N1CCOCC1)C1=NC=C(C=N1)C1=NC=CC(=C1)OC RHHQNPCKCPVJAV-UHFFFAOYSA-N 0.000 description 1
• CZCZUCJRJUDEJV-UHFFFAOYSA-N [3-(1-hydroxyethyl)-1-[5-(4-methylpyridin-2-yl)pyrimidin-2-yl]indazol-6-yl]-morpholin-4-ylmethanone Chemical compound OC(C)C1=NN(C2=CC(=CC=C12)C(=O)N1CCOCC1)C1=NC=C(C=N1)C1=NC=CC(=C1)C CZCZUCJRJUDEJV-UHFFFAOYSA-N 0.000 description 1
• LPVGVRPRTOSRGN-UHFFFAOYSA-N [3-cyclopropyl-1-(5-phenylpyrimidin-2-yl)indazol-6-yl]-morpholin-4-ylmethanone Chemical compound O=C(N1CCOCC1)C1=CC2=C(C=C1)C(=NN2C1=NC=C(C=N1)C1=CC=CC=C1)C1CC1 LPVGVRPRTOSRGN-UHFFFAOYSA-N 0.000 description 1
• ACXBSUKWSODDCR-UHFFFAOYSA-N [3-cyclopropyl-1-[5-(2-fluoro-5-methylsulfanylphenyl)pyrimidin-2-yl]indazol-6-yl]-morpholin-4-ylmethanone Chemical compound C1(CC1)C1=NN(C2=CC(=CC=C12)C(=O)N1CCOCC1)C1=NC=C(C=N1)C1=C(C=CC(=C1)SC)F ACXBSUKWSODDCR-UHFFFAOYSA-N 0.000 description 1
• UQIWVMJPMGQXJK-UHFFFAOYSA-N [3-cyclopropyl-1-[5-(2-fluoro-5-methylsulfinylphenyl)pyrimidin-2-yl]indazol-6-yl]-morpholin-4-ylmethanone Chemical compound C1(CC1)C1=NN(C2=CC(=CC=C12)C(=O)N1CCOCC1)C1=NC=C(C=N1)C1=C(C=CC(=C1)S(=O)C)F UQIWVMJPMGQXJK-UHFFFAOYSA-N 0.000 description 1
• OLNJLAQQCCOLCS-UHFFFAOYSA-N [3-cyclopropyl-1-[5-(2-fluoro-5-methylsulfonylphenyl)pyrimidin-2-yl]indazol-6-yl]-morpholin-4-ylmethanone Chemical compound C1(CC1)C1=NN(C2=CC(=CC=C12)C(=O)N1CCOCC1)C1=NC=C(C=N1)C1=C(C=CC(=C1)S(=O)(=O)C)F OLNJLAQQCCOLCS-UHFFFAOYSA-N 0.000 description 1
• KUTBZDSJVVCEMD-UHFFFAOYSA-N [3-cyclopropyl-1-[5-(2-fluorophenyl)pyrimidin-2-yl]pyrazolo[4,3-c]pyridin-6-yl]-morpholin-4-ylmethanone Chemical compound C1(CC1)C1=NN(C2=C1C=NC(=C2)C(=O)N1CCOCC1)C1=NC=C(C=N1)C1=C(C=CC=C1)F KUTBZDSJVVCEMD-UHFFFAOYSA-N 0.000 description 1
• DILQFVZJLQNDGV-UHFFFAOYSA-N [3-cyclopropyl-1-[5-(5-ethoxy-2-fluorophenyl)pyrimidin-2-yl]indazol-6-yl]-morpholin-4-ylmethanone Chemical compound C1(CC1)C1=NN(C2=CC(=CC=C12)C(=O)N1CCOCC1)C1=NC=C(C=N1)C1=C(C=CC(=C1)OCC)F DILQFVZJLQNDGV-UHFFFAOYSA-N 0.000 description 1
• LXRCHDWOLSYPSP-UHFFFAOYSA-N [3-cyclopropyl-1-[5-[2-fluoro-5-(2-hydroxypropan-2-yl)phenyl]pyrimidin-2-yl]indazol-6-yl]-morpholin-4-ylmethanone Chemical compound C1(CC1)C1=NN(C2=CC(=CC=C12)C(=O)N1CCOCC1)C1=NC=C(C=N1)C1=C(C=CC(=C1)C(C)(C)O)F LXRCHDWOLSYPSP-UHFFFAOYSA-N 0.000 description 1
• PDNWMBPYHBDRPG-UHFFFAOYSA-N [3-methylsulfinyl-1-(5-phenylpyrimidin-2-yl)indazol-6-yl]-morpholin-4-ylmethanone Chemical compound CS(=O)C1=NN(C2=CC(=CC=C12)C(=O)N1CCOCC1)C1=NC=C(C=N1)C1=CC=CC=C1 PDNWMBPYHBDRPG-UHFFFAOYSA-N 0.000 description 1
• DQGHTFZEBAWEQR-UHFFFAOYSA-N [3-methylsulfinyl-1-(5-phenylpyrimidin-2-yl)indazol-6-yl]-piperazin-1-ylmethanone Chemical compound CS(=O)C1=NN(C2=CC(=CC=C12)C(=O)N1CCNCC1)C1=NC=C(C=N1)C1=CC=CC=C1 DQGHTFZEBAWEQR-UHFFFAOYSA-N 0.000 description 1
• BGRCNJBEXMBPQB-UHFFFAOYSA-N [3-methylsulfonyl-1-(5-phenylpyrimidin-2-yl)indazol-6-yl]-morpholin-4-ylmethanone Chemical compound CS(=O)(=O)C1=NN(C2=CC(=CC=C12)C(=O)N1CCOCC1)C1=NC=C(C=N1)C1=CC=CC=C1 BGRCNJBEXMBPQB-UHFFFAOYSA-N 0.000 description 1
• SJZAPSHKTOTRBQ-UHFFFAOYSA-N [dimethylamino(triazolo[4,5-b]pyridin-1-yl)methylidene]-dimethylazanium Chemical compound C1=CC=C2[N+](=C(N(C)C)N(C)C)N=NC2=N1 SJZAPSHKTOTRBQ-UHFFFAOYSA-N 0.000 description 1
• PDKXJKWLFFZPPF-UHFFFAOYSA-N [dimethylamino-(3-oxidotriazolo[4,5-b]pyridin-3-ium-1-yl)methylidene]-dimethylazanium Chemical compound C1=CC=C2N(C(N(C)C)=[N+](C)C)N=[N+]([O-])C2=N1 PDKXJKWLFFZPPF-UHFFFAOYSA-N 0.000 description 1
• 239000013543 active substance Substances 0.000 description 1
• 125000002015 acyclic group Chemical group 0.000 description 1
• 239000000654 additive Substances 0.000 description 1
• 239000000443 aerosol Substances 0.000 description 1
• 150000001299 aldehydes Chemical class 0.000 description 1
• 150000001338 aliphatic hydrocarbons Chemical class 0.000 description 1
• 229910001854 alkali hydroxide Inorganic materials 0.000 description 1
• 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
• 125000003545 alkoxy group Chemical group 0.000 description 1
• 150000004791 alkyl magnesium halides Chemical class 0.000 description 1
• 108020004101 alpha-2 Adrenergic Receptor Proteins 0.000 description 1
• HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
• 102000015006 alpha2-adrenergic receptor activity proteins Human genes 0.000 description 1
• 239000007864 aqueous solution Substances 0.000 description 1
• 238000000065 atmospheric pressure chemical ionisation Methods 0.000 description 1
• 238000010533 azeotropic distillation Methods 0.000 description 1
• 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
• 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
• 125000005874 benzothiadiazolyl group Chemical group 0.000 description 1
• 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
• 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
• 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 1
• 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
• 239000011230 binding agent Substances 0.000 description 1
• IPWKHHSGDUIRAH-UHFFFAOYSA-N bis(pinacolato)diboron Chemical compound O1C(C)(C)C(C)(C)OB1B1OC(C)(C)C(C)(C)O1 IPWKHHSGDUIRAH-UHFFFAOYSA-N 0.000 description 1
• 230000037396 body weight Effects 0.000 description 1
• 239000000872 buffer Substances 0.000 description 1
• 102100037092 cAMP-specific 3',5'-cyclic phosphodiesterase 4A Human genes 0.000 description 1
• 102100029169 cAMP-specific 3',5'-cyclic phosphodiesterase 4C Human genes 0.000 description 1
• TVFDJXOCXUVLDH-UHFFFAOYSA-N caesium atom Chemical compound [Cs] TVFDJXOCXUVLDH-UHFFFAOYSA-N 0.000 description 1
• 229910000024 caesium carbonate Inorganic materials 0.000 description 1
• 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
• 125000002837 carbocyclic group Chemical group 0.000 description 1
• 150000001718 carbodiimides Chemical class 0.000 description 1
• 229910052799 carbon Inorganic materials 0.000 description 1
• BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
• 239000012876 carrier material Substances 0.000 description 1
• 230000001413 cellular effect Effects 0.000 description 1
• 239000013522 chelant Substances 0.000 description 1
• 125000003636 chemical group Chemical group 0.000 description 1
• 238000003776 cleavage reaction Methods 0.000 description 1
• 239000012230 colorless oil Substances 0.000 description 1
• 229940125904 compound 1 Drugs 0.000 description 1
• 229940126214 compound 3 Drugs 0.000 description 1
• 229940125877 compound 31 Drugs 0.000 description 1
• 229940125898 compound 5 Drugs 0.000 description 1
• LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 1
• 230000002596 correlated effect Effects 0.000 description 1
• 239000006071 cream Substances 0.000 description 1
• 125000001162 cycloheptenyl group Chemical group C1(=CCCCCC1)* 0.000 description 1
• 125000006547 cyclononyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
• 125000000522 cyclooctenyl group Chemical group C1(=CCCCCCC1)* 0.000 description 1
• WLVKDFJTYKELLQ-UHFFFAOYSA-N cyclopropylboronic acid Chemical compound OB(O)C1CC1 WLVKDFJTYKELLQ-UHFFFAOYSA-N 0.000 description 1
• 230000003111 delayed effect Effects 0.000 description 1
• 238000011161 development Methods 0.000 description 1
• 125000004988 dibenzothienyl group Chemical group C1(=CC=CC=2SC3=C(C21)C=CC=C3)* 0.000 description 1
• WMKGGPCROCCUDY-PHEQNACWSA-N dibenzylideneacetone Chemical compound C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 WMKGGPCROCCUDY-PHEQNACWSA-N 0.000 description 1
• VILAVOFMIJHSJA-UHFFFAOYSA-N dicarbon monoxide Chemical group [C]=C=O VILAVOFMIJHSJA-UHFFFAOYSA-N 0.000 description 1
• HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
• 230000001079 digestive effect Effects 0.000 description 1
• 229940043279 diisopropylamine Drugs 0.000 description 1
• 239000003085 diluting agent Substances 0.000 description 1
• AAXGWYDSLJUQLN-UHFFFAOYSA-N diphenyl(propyl)phosphane Chemical compound C=1C=CC=CC=1P(CCC)C1=CC=CC=C1 AAXGWYDSLJUQLN-UHFFFAOYSA-N 0.000 description 1
• 239000007884 disintegrant Substances 0.000 description 1
• 239000006196 drop Substances 0.000 description 1
• 239000000839 emulsion Substances 0.000 description 1
• XORZIVNVCBNFHW-UHFFFAOYSA-N ethyl 3-cyclopropyl-1-[5-(2-fluorophenyl)pyrimidin-2-yl]pyrazolo[4,3-c]pyridine-6-carboxylate Chemical compound C1(CC1)C1=NN(C2=C1C=NC(=C2)C(=O)OCC)C1=NC=C(C=N1)C1=C(C=CC=C1)F XORZIVNVCBNFHW-UHFFFAOYSA-N 0.000 description 1
• 239000002038 ethyl acetate fraction Substances 0.000 description 1
• PQVSTLUFSYVLTO-UHFFFAOYSA-N ethyl n-ethoxycarbonylcarbamate Chemical compound CCOC(=O)NC(=O)OCC PQVSTLUFSYVLTO-UHFFFAOYSA-N 0.000 description 1
• 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
• OGPBJKLSAFTDLK-UHFFFAOYSA-N europium atom Chemical compound [Eu] OGPBJKLSAFTDLK-UHFFFAOYSA-N 0.000 description 1
• GWQVMPWSEVRGPY-UHFFFAOYSA-N europium cryptate Chemical compound [Eu+3].N=1C2=CC=CC=1CN(CC=1N=C(C=CC=1)C=1N=C(C3)C=CC=1)CC(N=1)=CC(C(=O)NCCN)=CC=1C(N=1)=CC(C(=O)NCCN)=CC=1CN3CC1=CC=CC2=N1 GWQVMPWSEVRGPY-UHFFFAOYSA-N 0.000 description 1
• 238000002474 experimental method Methods 0.000 description 1
• 239000000284 extract Substances 0.000 description 1
• 208000011323 eye infectious disease Diseases 0.000 description 1
• 239000000945 filler Substances 0.000 description 1
• 239000012467 final product Substances 0.000 description 1
• 238000005187 foaming Methods 0.000 description 1
• 238000009472 formulation Methods 0.000 description 1
• 239000003205 fragrance Substances 0.000 description 1
• 210000001035 gastrointestinal tract Anatomy 0.000 description 1
• 239000000499 gel Substances 0.000 description 1
• 230000026030 halogenation Effects 0.000 description 1
• 238000005658 halogenation reaction Methods 0.000 description 1
• 231100000869 headache Toxicity 0.000 description 1
• 238000010438 heat treatment Methods 0.000 description 1
• 201000005787 hematologic cancer Diseases 0.000 description 1
• 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
• 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 238000007327 hydrogenolysis reaction Methods 0.000 description 1
• 230000007062 hydrolysis Effects 0.000 description 1
• 238000006460 hydrolysis reaction Methods 0.000 description 1
• USZLCYNVCCDPLQ-UHFFFAOYSA-N hydron;n-methoxymethanamine;chloride Chemical compound Cl.CNOC USZLCYNVCCDPLQ-UHFFFAOYSA-N 0.000 description 1
• 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
• 206010020718 hyperplasia Diseases 0.000 description 1
• 230000002390 hyperplastic effect Effects 0.000 description 1
• 239000005457 ice water Substances 0.000 description 1
• 125000002883 imidazolyl group Chemical group 0.000 description 1
• 239000012535 impurity Substances 0.000 description 1
• 238000011065 in-situ storage Methods 0.000 description 1
• 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
• 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
• 239000003999 initiator Substances 0.000 description 1
• 150000007529 inorganic bases Chemical class 0.000 description 1
• 238000007918 intramuscular administration Methods 0.000 description 1
• 238000007912 intraperitoneal administration Methods 0.000 description 1
• 238000001990 intravenous administration Methods 0.000 description 1
• 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
• 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
• 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
• 125000001786 isothiazolyl group Chemical group 0.000 description 1
• 239000003446 ligand Substances 0.000 description 1
• 239000008297 liquid dosage form Substances 0.000 description 1
• DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 1
• 229940040692 lithium hydroxide monohydrate Drugs 0.000 description 1
• 239000006210 lotion Substances 0.000 description 1
• 239000000314 lubricant Substances 0.000 description 1
• 230000014759 maintenance of location Effects 0.000 description 1
• 238000004519 manufacturing process Methods 0.000 description 1
• 229910052751 metal Inorganic materials 0.000 description 1
• 239000002184 metal Substances 0.000 description 1
• CKJNUZNMWOVDFN-UHFFFAOYSA-N methanone Chemical compound O=[CH-] CKJNUZNMWOVDFN-UHFFFAOYSA-N 0.000 description 1
• TUSICEWIXLMXEY-UHFFFAOYSA-N methyl 1h-indazole-6-carboxylate Chemical compound COC(=O)C1=CC=C2C=NNC2=C1 TUSICEWIXLMXEY-UHFFFAOYSA-N 0.000 description 1
• AYYOZKHMSABVRP-UHFFFAOYSA-N methyl 1h-indole-6-carboxylate Chemical compound COC(=O)C1=CC=C2C=CNC2=C1 AYYOZKHMSABVRP-UHFFFAOYSA-N 0.000 description 1
• IVDWDLLIQZQTCK-UHFFFAOYSA-N methyl 3-(1-hydroxyethyl)-2H-indazole-6-carboxylate Chemical compound COC(=O)C1=CC2=C(C=C1)C(=NN2)C(C)O IVDWDLLIQZQTCK-UHFFFAOYSA-N 0.000 description 1
• GKTCZCGEKPMROK-UHFFFAOYSA-N methyl 3-cyclopropyl-2H-indazole-6-carboxylate Chemical compound C1(CC1)C1=NNC2=CC(=CC=C12)C(=O)OC GKTCZCGEKPMROK-UHFFFAOYSA-N 0.000 description 1
• VSXHXVGWOSYULI-UHFFFAOYSA-N methyl 3-iodo-2h-indazole-6-carboxylate Chemical compound C1=C(C(=O)OC)C=CC2=C(I)NN=C21 VSXHXVGWOSYULI-UHFFFAOYSA-N 0.000 description 1
• CKPSQUXIPHAGLQ-UHFFFAOYSA-N methyl 3-methyl-2h-indazole-6-carboxylate Chemical compound COC(=O)C1=CC=C2C(C)=NNC2=C1 CKPSQUXIPHAGLQ-UHFFFAOYSA-N 0.000 description 1
• MDPBECFOVYNJDT-UHFFFAOYSA-N methyl 3-methylsulfanyl-1-(5-phenylpyrimidin-2-yl)indazole-6-carboxylate Chemical compound COC(=O)C1=CC2=C(C=C1)C(SC)=NN2C1=NC=C(C=N1)C1=CC=CC=C1 MDPBECFOVYNJDT-UHFFFAOYSA-N 0.000 description 1
• QAGCIUOTBJAYAX-UHFFFAOYSA-N methyl 6-(morpholine-4-carbonyl)-1H-indazole-3-carboxylate Chemical compound N1(CCOCC1)C(=O)C1=CC=C2C(=NNC2=C1)C(=O)OC QAGCIUOTBJAYAX-UHFFFAOYSA-N 0.000 description 1
• 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
• 150000007522 mineralic acids Chemical class 0.000 description 1
• 210000004400 mucous membrane Anatomy 0.000 description 1
• MZRVEZGGRBJDDB-UHFFFAOYSA-N n-Butyllithium Substances [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 1
• MUWDEQLPHWVPPA-GOTSBHOMSA-N n-[6-oxo-6-[(3s,4s)-3-[(4-phenoxyphenyl)sulfonylamino]-4-sulfanylpyrrolidin-1-yl]hexyl]acetamide Chemical compound C1N(C(=O)CCCCCNC(=O)C)C[C@H](S)[C@H]1NS(=O)(=O)C(C=C1)=CC=C1OC1=CC=CC=C1 MUWDEQLPHWVPPA-GOTSBHOMSA-N 0.000 description 1
• 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
• 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
• 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• 238000007339 nucleophilic aromatic substitution reaction Methods 0.000 description 1
• 238000010534 nucleophilic substitution reaction Methods 0.000 description 1
• 239000002674 ointment Substances 0.000 description 1
• 150000007524 organic acids Chemical class 0.000 description 1
• 150000007530 organic bases Chemical class 0.000 description 1
• 125000001715 oxadiazolyl group Chemical group 0.000 description 1
• 230000001590 oxidative effect Effects 0.000 description 1
• 229910052763 palladium Inorganic materials 0.000 description 1
• LXNAVEXFUKBNMK-UHFFFAOYSA-N palladium(II) acetate Substances [Pd].CC(O)=O.CC(O)=O LXNAVEXFUKBNMK-UHFFFAOYSA-N 0.000 description 1
• 230000036961 partial effect Effects 0.000 description 1
• 239000008188 pellet Substances 0.000 description 1
• 230000035515 penetration Effects 0.000 description 1
• 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
• 239000000825 pharmaceutical preparation Substances 0.000 description 1
• 125000001484 phenothiazinyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 description 1
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
• 239000010452 phosphate Substances 0.000 description 1
• 239000002571 phosphodiesterase inhibitor Substances 0.000 description 1
• 125000005542 phthalazyl group Chemical group 0.000 description 1
• IWELDVXSEVIIGI-UHFFFAOYSA-N piperazin-2-one Chemical compound O=C1CNCCN1 IWELDVXSEVIIGI-UHFFFAOYSA-N 0.000 description 1
• 239000011505 plaster Substances 0.000 description 1
• 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
• 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
• CHKVPAROMQMJNQ-UHFFFAOYSA-M potassium bisulfate Chemical compound [K+].OS([O-])(=O)=O CHKVPAROMQMJNQ-UHFFFAOYSA-M 0.000 description 1
• 229910000343 potassium bisulfate Inorganic materials 0.000 description 1
• TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
• LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
• 239000000843 powder Substances 0.000 description 1
• 239000002243 precursor Substances 0.000 description 1
• 239000003755 preservative agent Substances 0.000 description 1
• 150000003138 primary alcohols Chemical class 0.000 description 1
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
• 108090000765 processed proteins & peptides Proteins 0.000 description 1
• 125000006239 protecting group Chemical group 0.000 description 1
• 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
• 125000003373 pyrazinyl group Chemical group 0.000 description 1
• 125000002098 pyridazinyl group Chemical group 0.000 description 1
• BATMYWDOUUWCJE-UHFFFAOYSA-N pyrimidin-1-ium;bromide Chemical compound Br.C1=CN=CN=C1 BATMYWDOUUWCJE-UHFFFAOYSA-N 0.000 description 1
• 125000000168 pyrrolyl group Chemical group 0.000 description 1
• 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
• 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
• 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
• 230000009467 reduction Effects 0.000 description 1
• 230000011514 reflex Effects 0.000 description 1
• 238000012552 review Methods 0.000 description 1
• 229930195734 saturated hydrocarbon Natural products 0.000 description 1
• 230000007017 scission Effects 0.000 description 1
• 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
• 125000003548 sec-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
• 150000003335 secondary amines Chemical class 0.000 description 1
• 239000008299 semisolid dosage form Substances 0.000 description 1
• WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical class [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 1
• 239000012279 sodium borohydride Substances 0.000 description 1
• 229910000033 sodium borohydride Inorganic materials 0.000 description 1
• RMBAVIFYHOYIFM-UHFFFAOYSA-M sodium methanethiolate Chemical compound [Na+].[S-]C RMBAVIFYHOYIFM-UHFFFAOYSA-M 0.000 description 1
• GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical class [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 1
• AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
• 235000019345 sodium thiosulphate Nutrition 0.000 description 1
• 239000007909 solid dosage form Substances 0.000 description 1
• 238000007920 subcutaneous administration Methods 0.000 description 1
• 125000004434 sulfur atom Chemical group 0.000 description 1
• 239000000829 suppository Substances 0.000 description 1
• 208000024891 symptom Diseases 0.000 description 1
• DQQJBEAXSOOCPG-SSDOTTSWSA-N tert-butyl n-[(3r)-pyrrolidin-3-yl]carbamate Chemical compound CC(C)(C)OC(=O)N[C@@H]1CCNC1 DQQJBEAXSOOCPG-SSDOTTSWSA-N 0.000 description 1
• 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• CBXCPBUEXACCNR-UHFFFAOYSA-N tetraethylammonium Chemical compound CC[N+](CC)(CC)CC CBXCPBUEXACCNR-UHFFFAOYSA-N 0.000 description 1
• 125000003831 tetrazolyl group Chemical group 0.000 description 1
• 238000011287 therapeutic dose Methods 0.000 description 1
• 231100001274 therapeutic index Toxicity 0.000 description 1
• 125000001113 thiadiazolyl group Chemical group 0.000 description 1
• 238000001269 time-of-flight mass spectrometry Methods 0.000 description 1
• 230000000699 topical effect Effects 0.000 description 1
• 231100000331 toxic Toxicity 0.000 description 1
• 230000002588 toxic effect Effects 0.000 description 1
• 231100000419 toxicity Toxicity 0.000 description 1
• 230000001988 toxicity Effects 0.000 description 1
• 230000007704 transition Effects 0.000 description 1
• 125000004306 triazinyl group Chemical group 0.000 description 1
• 125000001425 triazolyl group Chemical group 0.000 description 1
• MWKJTNBSKNUMFN-UHFFFAOYSA-N trifluoromethyltrimethylsilane Chemical compound C[Si](C)(C)C(F)(F)F MWKJTNBSKNUMFN-UHFFFAOYSA-N 0.000 description 1
• BWHDROKFUHTORW-UHFFFAOYSA-O tritert-butylphosphanium Chemical compound CC(C)(C)[PH+](C(C)(C)C)C(C)(C)C BWHDROKFUHTORW-UHFFFAOYSA-O 0.000 description 1
• 125000004417 unsaturated alkyl group Chemical group 0.000 description 1
• 125000005500 uronium group Chemical group 0.000 description 1
• 229920002554 vinyl polymer Polymers 0.000 description 1
• 239000003039 volatile agent Substances 0.000 description 1
• 239000003643 water by type Substances 0.000 description 1